Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov 25;5(4):00247-2018.
doi: 10.1183/23120541.00247-2018. eCollection 2019 Oct.

Serum levels of L1-ORF1p and airflow limitation

Stefano Guerra  1   2   3 , Monica M Vasquez  1 , Pasano Bojang Jr  2 , Irma N Ramos  4 , Duane L Sherrill  1 , Fernando D Martinez  1 , Marilyn Halonen  1   5 , Kenneth S Ramos  1   2   6
Affiliations

Serum levels of L1-ORF1p and airflow limitation

Stefano Guerra et al. ERJ Open Res. .

Abstract

In a population-based study, higher circulating levels of L1-ORF1p were associated with lower lung function levels and increased risk for airflow limitation among former smokers http://bit.ly/2ZEIjNv.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: S. Guerra reports grants from the NIH during the conduct of the study. Conflict of interest: M.M. Vasquez has nothing to disclose. Conflict of interest: P. Bojang Jr has patent WO2017172839A1 (Use of biomarkers associated with LINE-1) issued. Conflict of interest: I.N. Ramos has nothing to disclose. Conflict of interest: D.L. Sherrill has nothing to disclose. Conflict of interest: F.D. Martinez reports grants from the National Institutes of Health (NIH)/National Heart, Lung and Blood Institute (HL139054, HL056177, HL132523, HL091889, HL130045 and HL098112), NIH/National Institute of Environmental Health Sciences (ES006694), NIH/National Institute of Allergy and Infectious Diseases (AI126694), NIH/Office of Director (OD023282) and Johnson & Johnson (UA009253-0001), and personal fees for consultancy from Copeval and Commense Inc., outside the submitted work. Conflict of interest: M. Halonen reports grants from the National Institutes of Health during the conduct of the study. Conflict of interest: K.S. Ramos reports grants from the National Institutes of Health during the conduct of the study. He holds patent W02017172839A1 (Use of biomarkers associated with LINE-1) and patent 2019 62/787444 (Systems and methods for characterizing and treating disease).

References

    1. Ramos KS, Teneng I, Montoya-Durango DE, et al. . The intersection of genetics and epigenetics: reactivation of mammalian LINE-1 retrotransposons by environmental injury In: Jirtle RL, Tyson FL, eds. Environmental Epigenomics in Health and Disease: Epigenetics and Disease Origins. Heidelberg, Springer, 2013; pp. 127–160.
    1. Bojang P Jr, Ramos KS. Epigenetic reactivation of LINE-1 retrotransposon disrupts NuRD corepressor functions and induces oncogenic transformation in human bronchial epithelial cells. Mol Oncol 2018; 12: 1342–1357. - PMC - PubMed
    1. Reyes-Reyes EM, Aispuro I, Tavera-Garcia MA, et al. . LINE-1 couples EMT programming with acquisition of oncogenic phenotypes in human bronchial epithelial cells. Oncotarget 2017; 8: 103828–103842. - PMC - PubMed
    1. Imperatori A, Sahnane N, Rotolo N, et al. . LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer. Lung Cancer 2017; 108: 83–89. - PubMed
    1. Lange NE, Sordillo J, Tarantini L, et al. . Alu and LINE-1 methylation and lung function in the normative ageing study. BMJ Open 2012; 2: e001231. - PMC - PubMed

LinkOut - more resources